Sun Pharmaceuticals Industries Ltd

Sun Pharmaceutical shares fell about 1.0% to ₹1,943 after US President Donald Trump announced steep tariffs on imported generics (100% from August 2028, then up to 200% by 2029). The move is likely to hit exports as Sun Pharmaceutical prepares its June quarterly results. Analysts remain, on average, positive with a "Buy" rating and a 12‑month target of ₹2,047; peers also slipped, dragging the Nifty 50 down 0.6%. » More on de.investing.com

Sun Pharmaceutical reported a net profit of 27.14 billion rupees for the March quarter, up 26.2% and slightly above estimates. Rising expenses, mainly for research and development, pushed the core margin down from 28.7% to 27.1% and weighed on the stock, which fell as much as 3.1% after the release. The specialty drugs business grew 20% and accounted for just under a quarter of sales, while US sales dipped slightly; the company has also made a cash offer of US$11.75 billion for Organon. » More on de.investing.com

Sun Pharma will buy Organon for $11.75 billion in cash plus debt, paying $14 per share, and the deal is expected to close in early 2027 after regulatory approvals. The acquisition propels Sun Pharma into the top 25 global drugmakers and adds a higher-margin portfolio in women’s health and biosimilars, reducing reliance on commodity generics and the U.S. market. Organon carries about $8.6 billion of debt and generates roughly $3.7 billion in revenue from mature brands, leaving the combined group with a projected net debt-to-EBITDA of 2.3x and limited room for error. Key risks include antitrust approvals, deleveraging strategy, and integration execution. » More on finance.yahoo.com